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SMAD3 and SMAD4 have a more 
dominant role than SMAD2 in 
TGFβ-induced chondrogenic 
differentiation of bone marrow-
derived mesenchymal stem cells
Laurie M. G. de Kroon1,2, Roberto Narcisi2, Guus G. H. van den Akker1, Elly L. Vitters1, 
Esmeralda N. Blaney Davidson1, Gerjo J. V. M. van Osch2,3 & Peter M. van der Kraan1
To improve cartilage formation by bone marrow-derived mesenchymal stem cells (BMSCs), the 
signaling mechanism governing chondrogenic differentiation requires better understanding. 
We previously showed that the transforming growth factor-β (TGFβ) receptor ALK5 is crucial for 
chondrogenesis induced by TGFβ. ALK5 phosphorylates SMAD2 and SMAD3 proteins, which then 
form complexes with SMAD4 to regulate gene transcription. By modulating the expression of SMAD2, 
SMAD3 and SMAD4 in human BMSCs, we investigated their role in TGFβ-induced chondrogenesis. 
Activation of TGFβ signaling, represented by SMAD2 phosphorylation, was decreased by SMAD2 
knockdown and highly increased by SMAD2 overexpression. Moreover, TGFβ signaling via the 
alternative SMAD1/5/9 pathway was strongly decreased by SMAD4 knockdown. TGFβ-induced 
chondrogenesis of human BMSCs was strongly inhibited by SMAD4 knockdown and only mildly 
inhibited by SMAD2 knockdown. Remarkably, both knockdown and overexpression of SMAD3 blocked 
chondrogenic differentiation. Chondrogenesis appears to rely on a delicate balance in the amount of 
SMAD3 and SMAD4 as it was not enhanced by SMAD4 overexpression and was inhibited by SMAD3 
overexpression. Furthermore, this study reveals that TGFβ-activated phosphorylation of SMAD2 and 
SMAD1/5/9 depends on the abundance of SMAD4. Overall, our findings suggest a more dominant role 
for SMAD3 and SMAD4 than SMAD2 in TGFβ-induced chondrogenesis of human BMSCs.
Joint injuries frequently cause articular cartilage lesions that do not heal well in adults as articular cartilage has 
poor regenerative capacity. Since bone marrow-derived mesenchymal stem cells (BMSCs) can chondrogenically 
differentiate, they are promising for cell-based regeneration of damaged articular cartilage. Chondrogenic dif-
ferentiation is potently induced by transforming growth factor-β (TGFβ )1–3. However, cartilage tissue formed by 
BMSC-derived chondrocytes does not completely resemble native articular cartilage as these cells tend to lose 
the chondrogenic phenotype due to hypertrophic differentiation4–8. Therefore, understanding how mediators of 
TGFβ signal transduction govern chondrogenesis will be crucial to improve cartilage regeneration by BMSCs.
Binding of TGFβ to its type II serine/threonine receptor TGFBR2 activates the type I receptor TGFBR1, also 
termed activin receptor-like kinase 5 (ALK5), to intracellularly phosphorylate receptor-regulated SMAD proteins 
(R-SMADs). Activated R-SMADs form complexes with co-factor SMAD4 and these complexes translocate to 
the nucleus where they regulate gene transcription9. Previously, we demonstrated that either blocking the kinase 
activity or downregulating the expression of ALK5 in human BMSCs inhibits chondrogenesis6,10, indicating an 
important role for TGFβ signaling via ALK5 in chondrogenic differentiation of BMSCs.
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ALK5 can activate two R-SMADs, SMAD2 and SMAD3, which share similar structures including a 
Mad-Homology 1 (MH1) domain, linker region and MH2 domain9,11. Despite their similarities, SMAD2 and 
SMAD3 have a differential role in TGFβ signal transduction12–15. Whereas Smad2 knockout mice die during gas-
trulation16,17, Smad3 knockout mice develop cartilage and survive for several months after birth18–20. Moreover, 
SMAD3, but not SMAD2, is involved in enhanced transcriptional activity of SRY (Sex Determining Region Y)-Box 
9 (SOX9); a master regulator of chondrogenesis, in human mesenchymal stem cells21,22. In contrast to SMAD3, 
SMAD2 lacks the MH1 domain. Therefore, SMAD2 cannot bind DNA without complex formation with SMAD4, 
which may explain the differential effects of SMAD2 and SMAD323–27. However, whether SMAD2 and SMAD3 
have a different function during TGFβ -induced chondrogenic differentiation of human BMSCs remains largely 
unknown. Also the specific role of SMAD4 in chondrogenesis of human BMSCs has not been investigated. In 
mice, deletion of Smad4 causes early embryonic death28,29. Therefore, tissue-specific Smad4 knockout mice have 
been generated. Conditional deletion of Smad4 in the limb bud mesenchyme of mice leads to an absence of 
cartilage elements prefiguring the limb skeleton30,31, indicating that SMAD4 is required for cartilage formation. 
Furthermore, chondrocyte-specific Smad4 knockout mice exhibit dwarfism and impaired growth plate organiza-
tion32. Similarly, Smad3 knockout mice have forelimb malformations, are smaller than wild-type mice and they 
develop spontaneous joint degeneration resembling the degenerative joint disease osteoarthritis in humans18,19. In 
humans, mutations in SMAD3 lead to skeletal anomalies and early-onset of osteoarthritis33–36. Moreover, SMAD3 
is required for TGFβ -mediated suppression of hypertrophic differentiation of human articular chondrocytes37,38. 
Although SMAD3 does not appear directly required for embryonic cartilage and joint development, SMAD3 
seems to be important for maintaining a stable cartilage phenotype by preventing cartilage degeneration.
Since SMAD2, SMAD3 and SMAD4 have been shown to differentially regulate TGFβ signaling and to 
have distinct functions during in vivo cartilage development and maintenance, we investigated their role in 
TGFβ -induced signaling and chondrogenesis of human BMSCs. We knocked down and overexpressed either 
SMAD2, SMAD3 or SMAD4 in human fetal BMSCs and determined the effects on TGFβ -activated SMAD phos-
phorylation and induction of chondrogenic differentiation.
Results
Efficient knockdown and overexpression of SMAD2, SMAD3 and SMAD4. To study the role of 
SMAD2, SMAD3 and SMAD4 in TGFβ -induced SMAD phosphorylation and chondrogenesis of human BMSCs, 
their expression was modulated in human fetal BMSCs using short hairpin RNA (shRNA)-mediated knockdown 
and adenoviral (ad)-mediated overexpression.
We confirmed efficient shRNA-mediated knockdown of SMAD2 (Fig. 1a,b), SMAD3 (Fig. 1c,d) and SMAD4 
(Fig. 1e,f) at the mRNA and protein level. In addition, we observed that SMAD2 (Fig. 1a) and SMAD3 (Fig. 1c) 
mRNA levels, but not their protein levels (Fig. 1b,d), were increased in SMAD4-shRNA compared to Ctrl-shRNA. 
Although gene expression of SMAD3 (Fig. 1c) and SMAD4 (Fig. 1e) was similar between SMAD2-shRNA and 
Ctrl-shRNA, their protein expression (Fig. 1d,f) was decreased in SMAD2-shRNA. Next, we verified adenovi-
ral overexpression of SMAD2 (Fig. 2a,b), SMAD3 (Fig. 2c,d) and SMAD4 (Fig. 2e,f) at gene and protein level. 
Notably, only SMAD4 protein (Fig. 2f) was slightly reduced in ad-SMAD2 compared to ad-LacZ. Thus, these data 
confirm efficient knockdown and overexpression of SMAD2, SMAD3 and SMAD4.
TGFβ-activated phosphorylation of R-SMADs is altered by knockdown and overexpression of 
SMAD2, SMAD3 or SMAD4. TGFβ signaling appears to be a straightforward cascade in which the ALK5 
receptor phosphorylates SMAD2 and SMAD3, which upon binding to SMAD4 translocate to the nucleus where 
they regulate gene transcription9. However, this system is more complex as multiple mechanisms have been dis-
covered that control TGFβ signal transduction39. Since it remained unknown whether R-SMAD phosphorylation 
depends on the amount of SMAD2 and SMAD3 present, we investigated whether modulating the expression 
of SMAD2 and SMAD3 affected TGFβ -activated phosphorylation of R-SMADs. We only show the effects on 
phosphorylated SMAD2 (pSMAD2) due to difficult detection of pSMAD3. First, we verified that TGFβ induced 
pSMAD2 in Ctrl-shRNA cells (Fig. 3a) and in ad-LacZ cells compared to no stimulation (Fig. 3b). TGFβ -activated 
SMAD2 phosphorylation was reduced in the SMAD2-shRNA condition (Fig. 3a) and it was enhanced in 
ad-SMAD2 (Fig. 3b). No effect on pSMAD2 was observed with SMAD3-shRNA (Fig. 3a) or ad-SMAD3 (Fig. 3b). 
Moreover, to determine if co-factor SMAD4 is involved in TGFβ -activated R-SMAD phosphorylation, the expres-
sion of SMAD4 was modulated. We found that pSMAD2 was lower in SMAD4-shRNA than in Ctrl-shRNA 
(Fig. 3a) and was similar between ad-SMAD4 and ad-LacZ (Fig. 3b).
Next to SMAD2/3, TGFβ can activate SMAD1/5/9, and both these R-SMAD signaling pathways are important 
for chondrogenic induction6,10. Moreover, the TGFβ receptor ALK5 is required for TGFβ -activated phosphoryl-
ation of SMAD2/3 and SMAD1/5/940. Hence, we hypothesized there could be competition between SMAD2/3 
and SMAD1/5/9 for phosphorylation by ALK5. We confirmed SMAD1/5/9 phosphorylation (pSMAD1/5/9) 
in response to TGFβ stimulation compared to no stimulation in Ctrl-shRNA (Fig. 3c) and ad-LacZ (Fig. 3d). 
TGFβ -induced pSMAD1/5/9 was higher in SMAD2-shRNA and SMAD3-shRNA than in Ctrl-shRNA (Fig. 3c). 
Although SMAD1/5/9 phosphorylation was similar between ad-SMAD2 and ad-LacZ, it was slightly reduced 
in ad-SMAD3 (Fig. 3d). Next, we studied the involvement of SMAD4 in TGFβ -activated SMAD1/5/9 phos-
phorylation. We observed that in the SMAD4-shRNA condition TGFβ stimulation did not lead to induction of 
pSMAD1/5/9 (Fig. 3c), whereas TGFβ -induced pSMAD1/5/9 was comparable between ad-SMAD4 and ad-LacZ 
(Fig. 3d).
Taken together, these data demonstrate that activation of the SMAD2/3 and SMAD1/5/9 signaling path-
ways by TGFβ was affected by modulating SMAD2, SMAD3 or SMAD4 expression, indicating that the levels of 
TGFβ -induced phosphorylated R-SMADs depend on the amount of R-SMAD2/3 and co-SMAD4.
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Knocking down either SMAD3 or SMAD4 strongly inhibits chondrogenesis. We determined the 
contribution of SMAD2, SMAD3 and SMAD4 during TGFβ -induced chondrogenic differentiation by knocking 
down the expression of these SMADs and culturing the BMSCs in pellets in chondrogenic medium containing 
TGFβ . After 1, 7 and 14 days we evaluated expression of chondrogenesis-specific genes ACAN, COL2A1 and 
SOX9, formation of cartilage matrix and the macroscopic appearance of the BMSC pellets.
In 1, 7 and 14 days-cultured BMSC pellets, ACAN (Fig. 4a), COL2A1 (Fig. 4b) and SOX9 (Fig. 4c) were sim-
ilarly expressed in the SMAD2-shRNA and Ctrl-shRNA condition, except for a significant decrease in COL2A1 
expression at day 1 in SMAD2-shRNA (p = 0.007). Although ACAN and SOX9 expression were mildly affected 
by SMAD3-shRNA, transcription of COL2A1 was significantly inhibited by SMAD3-shRNA at day 1 (p = 0.007), 
day 7 (p < 0.001) and day 14 (p = 0.029). Furthermore, a strong and significant inhibition of ACAN, COL2A1 
and SOX9 expression was observed in SMAD4-shRNA at all time points (p < 0.01 for all genes and time points).
Next, we analyzed cartilage matrix deposition by determining the presence of glycosaminoglycans (GAGs) 
and collagen type II protein. In addition, we measured the pellet size. Compared to control, TGFβ -induced dep-
osition of GAGs was not inhibited by SMAD2-shRNA at day 14 (Fig. 4d), whereas it was significantly inhibited 
by SMAD3-shRNA (p = 0.010 at day 7; p < 0.001 at day 14). The same was observed after correcting the GAG 
content for the amount of DNA per pellet (Fig. 4e; Supplementary Fig. S1). Despite stimulation with TGFβ , no 
GAGs were formed in pellets of BMSCs transduced with SMAD4-shRNA (Fig. 4d,e). Consistent with this, analyz-
ing the presence of GAGs and collagen type II protein in 14 days-cultured pellets by histology revealed that both 
cartilage components were similarly present in SMAD2-shRNA and Ctrl-shRNA, whereas they were reduced in 
SMAD3-shRNA and even absent in SMAD4-shRNA (Fig. 4f). These observations were reflected by the size of 
the pellets after 14 days of culturing. Compared to Ctrl-shRNA pellets, SMAD2-shRNA pellets had the same size, 
SMAD3-shRNA pellets were smaller and SMAD4-shRNA pellets were smallest (Fig. 4g).
Once BMSCs have differentiated into chondrocytes, they undergo hypertrophic maturation, which is 
characterized by enhanced expression of collagen type X α1 (COL10A1) and runt-related transcription factor 
Figure 1. Short hairpin RNA-mediated knockdown of SMAD2, SMAD3 and SMAD4 expression. Following 
lentiviral transduction with either SMAD2-shRNA, SMAD3-shRNA, SMAD4-shRNA or non-mammalian 
shRNA control (Ctrl-shRNA), human fetal BMSCs were cultured in chondrogenic medium for 1 day. Short 
hairpin RNA-mediated knockdown was evaluated by determining gene (RT-qPCR; (a,c,e) and protein (Western 
blot; (b,d,f) expression of SMAD2 (a,b), SMAD3 (c,d) and SMAD4 (e,f). Protein levels were normalized to 
GAPDH and expressed as relative to Ctrl-shRNA. Gene expression was normalized to the mean CT value of 
RPS27a and TBP. Data are expressed as % relative to normalized mRNA levels in Ctrl-shRNA. Bars represent 
mean + S.D. of triplicate pellets from 2 experiments. **p < 0.01; ***p < 0.001 compared to Ctrl-shRNA.
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2 (RUNX2)4–8. We observed that COL10A1 and RUNX2 mRNA levels were similar between SMAD2-shRNA, 
SMAD3-shRNA and Ctrl-shRNA in 7 and 14 days-cultured pellets (Supplementary Fig. S2a,b). In contrast, 
compared to Ctrl-shRNA, COL10A1 expression was lower in the SMAD4-shRNA than in the Ctrl-shRNA 
condition (Supplementary Fig. S2a), while SMAD4-shRNA had no significant effect on RUNX2 expression 
(Supplementary Fig. S2b).
Altogether, these results indicate that shRNA-mediated knockdown of SMAD2 had a minor inhibitory effect 
on TGFβ -induced chondrogenic differentiation of human BMSCs. However, SMAD3 knockdown strongly 
reduced cartilage deposition, and SMAD4 knockdown completely blocked chondrogenesis.
SMAD3 overexpression results in a strong inhibition of chondrogenesis. Since knockdown 
of SMAD2, SMAD3 and SMAD4 inhibited chondrogenesis, we investigated whether overexpression of these 
SMADs might enhance TGFβ -induced chondrogenic differentiation of human BMSCs.
Expression of ACAN (Fig. 5a), COL2A1 (Fig. 5b) and SOX9 (Fig. 5c) was comparable between the control con-
dition (ad-LacZ) and ad-SMAD2, ad-SMAD3 and ad-SMAD4 after 1 day of pellet culturing. In 7 days-cultured 
pellets ACAN, COL2A1 and SOX9 were slightly lower expressed in ad-SMAD2 than in ad-LacZ (ACAN: 
p = 0.016; COL2A1: p < 0.001; SOX9: p = 0.047). However, after 14 days only ACAN expression was significantly 
decreased in ad-SMAD2 compared to ad-LacZ (p = 0.038). At all time points expression of ACAN, COL2A1 and 
SOX9 was significantly reduced by ad-SMAD3 (p < 0.05 for all genes), whereas their expression was not affected 
by ad-SMAD4.
Deposition of GAGs (Fig. 5d) was significantly decreased in pellets of BMSCs transduced with ad-SMAD2 
compared to control after 7 days (p = 0.009) and 14 days (p = 0.003). However, this significant reduction was not 
observed when the GAG content was corrected for the DNA content (Fig. 5e; Supplementary Fig. S3). Pellets of 
ad-SMAD3-transduced BMSCs had a significantly lower amount of GAGs per pellet (Fig. 5d: p < 0.001 at day 7; 
p = 0.006 at day 14) and per μ g DNA (Fig. 5e; Supplementary Fig. S3; p = 0.007 at day 7; p < 0.001 at day 14) 
than the control condition. At all time points, GAG deposition (Fig. 5d,e) was similar between ad-SMAD4 and 
ad-LacZ. Histological analysis of 14 days-cultured pellets revealed that the abundance of GAGs and collagen 
type II protein (Fig. 5f) was similar between ad-SMAD2, ad-SMAD4 and ad-LacZ, whereas their abundance was 
strongly reduced in the ad-SMAD3 condition. In line with these observations, pellets of ad-SMAD2-transduced 
Figure 2. Adenoviral-mediated overexpression of SMAD2, SMAD3 and SMAD4. Human fetal BMSCs 
were transduced with adenovirus overexpressing SMAD2 (ad-SMAD2), ad-SMAD3, ad-SMAD4 or ad-LacZ as 
control, followed by culturing in chondrogenic medium for 1 day. To confirm overexpression, gene (RT-qPCR; 
(a,c,e) and protein (Western blot; (b,d,f) expression of SMAD2 (a,b), SMAD3 (c,d) and SMAD4 (e,f) were 
measured. Protein levels were normalized to GAPDH and expressed as relative to ad-LacZ. Gene expression 
data are presented as −Δ CT compared to the mean CT value of RPS27a and TBP. Bars represent mean + S.D. of 
triplicate pellets from 2 experiments. ***p < 0.001 compared to ad-LacZ.
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BMSCs were slightly smaller than control pellets, whereas pellets of ad-SMAD3-transduced BMSCs were much 
smaller (Fig. 5g). The pellet size was comparable between the ad-SMAD4 and ad-LacZ condition (Fig. 5g).
In addition, we found that chondrocyte hypertrophy markers, COL10A1 and RUNX2, were sim-
ilarly expressed between ad-LacZ and ad-SMAD4 after 7 and 14 days (Supplementary Fig. S4a,b). Although 
COL10A1 expression was lower in ad-SMAD2 than in ad-LacZ at day 7, the two conditions were compa-
rable at day 14 (Supplementary Fig. S4a). At both time points, RUNX2 mRNA levels were similar between 
ad-SMAD2 and ad-LacZ (Supplementary Fig. S4b). Strikingly, in the ad-SMAD3 condition COL10A1 mRNA 
was lower (Supplementary Fig. S4a), whereas RUNX2 mRNA was higher than in the ad-LacZ condition 
(Supplementary Fig. S4b).
Our data demonstrate that TGFβ -induced chondrogenesis was slightly inhibited by SMAD2 overexpression 
and not affected by SMAD4 overexpression, whereas it was strongly inhibited by SMAD3 overexpression.
Discussion
The pro-chondrogenic effect of TGFβ on human BMSCs is well-known, however, the contribution of the down-
stream signaling molecules SMAD2, SMAD3 and SMAD4 during chondrogenesis has been less well investigated. 
By using human fetal BMSCs as a model for TGFβ -induced chondrogenic differentiation, we demonstrate here 
that modulating SMAD2 expression had a minor effect on chondrogenesis. In contrast, knockdown as well as 
overexpression of SMAD3 strongly inhibited cartilage formation and SMAD4 knockdown completely blocked 
chondrogenesis.
To the best of our knowledge, the specific role of SMAD2 and SMAD3 during chondrogenic differentiation 
of human BMSCs has been studied in one study so far, which demonstrated that modulating SMAD2 expression 
does not affect chondrogenesis22. In contrast, we observed a slight reduction in cartilage formation when SMAD2 
was knocked down or overexpressed. We also found that SMAD2 knockdown led to reduced protein levels of 
SMAD3 and SMAD4, whereas Furumatsu et al. did not report an effect of SMAD2 knockdown on SMAD3 and 
SMAD4 expression22. Since knockdown of either SMAD3 or SMAD4 inhibited chondrogenesis, reduced SMAD3 
and SMAD4 abundance might explain why chondrogenesis was slightly inhibited by SMAD2 knockdown. Our 
Figure 3. TGFβ-activated phosphorylation of R-SMADs is affected by knockdown and overexpression 
of SMAD2, SMAD3 and SMAD4. The effects of shRNA-mediated knockdown and adenoviral-mediated 
overexpression of SMAD2, SMAD3 and SMAD4 on TGFβ -induced phosphorylation of SMAD2 (pSMAD2; 
(a,b) and pSMAD1/5/9 (c,d) were determined using Western blot. To confirm TGFβ -induced phosphorylation 
of SMAD2 and SMAD1/5/9, Ctrl-shRNA cells and ad-LacZ cells were either not stimulated (− ) or stimulated 
(+ ) with TGFβ in chondrogenic medium. Protein levels were normalized to GAPDH and expressed as relative 
to unstimulated Ctrl-shRNA or ad-LacZ.
www.nature.com/scientificreports/
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Figure 4. Chondrogenesis is mildly inhibited by SMAD2-shRNA, is strongly inhibited by SMAD3-shRNA 
and completely blocked by SMAD4-shRNA. Human fetal BMSCs were transduced (lentivirus) either with 
SMAD2-shRNA, SMAD3-shRNA, SMAD4-shRNA or Ctrl-shRNA and subsequently pellet-cultured for 1, 
7 or 14 days in chondrogenic medium with TGFβ . The effect of shRNA-mediated knockdown of SMAD2, 
SMAD3 and SMAD4 on chondrogenesis was determined by RT-qPCR analysis of the chondrogenesis-specific 
genes; ACAN (a), COL2A1 (b) and SOX9 (c), deposition of glycosaminoglycans (GAGs) per pellet (d) and 
per μ g DNA (e), histological examination of GAGs by Safranin O (Saf.O) staining and collagen type II by 
immunohistochemistry in sections of 14 days-cultured pellets (f), and macroscopic evaluation of 14 days-
cultured pellets (g). In (f) representative images of consecutive pellet sections per condition are shown and the 
scale bar represents 500 μ m. Gene expression data are presented as −Δ CT compared to the mean CT value of 
RPS27a and TBP. Bars represent mean + S.D. of triplicate pellets from 2 experiments. *p < 0.05; **p < 0.01; 
***p < 0.001 compared to Ctrl-shRNA.
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Figure 5. Chondrogenesis is strongly inhibited by SMAD3 overexpression, whereas it is mildly inhibited 
by SMAD2 overexpression and unaffected by SMAD4 overexpression. Human fetal BMSCs transduced either 
with adenoviral SMAD2 (ad-SMAD2), ad-SMAD3, ad-SMAD4 or ad-LacZ as control were pellet-cultured for 
1, 7 or 14 days in chondrogenic medium with TGFβ . The effect of SMAD overexpression on chondrogenesis 
was determined by RT-qPCR analysis of the chondrogenesis-specific genes; ACAN (a), COL2A1 (b) and SOX9 
(c), deposition of glycosaminoglycans (GAGs) per pellet (d) and per μ g DNA (e), histological examination of 
GAGs by Safranin O (Saf.O) staining and collagen type II by immunohistochemistry in sections of 14 days-
cultured pellets (f), and macroscopic evaluation of 14 days-cultured pellets (g). In (f) representative images of 
consecutive pellet sections per condition are shown and the scale bar represents 500 μ m. Gene expression data 
are presented as −Δ CT compared to the mean CT value of RPS27a and TBP. Bars represent mean + S.D. of 
triplicate pellets from 2 experiments. *p < 0.05; **p < 0.01; ***p < 0.001 compared to ad-LacZ.
www.nature.com/scientificreports/
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finding that TGFβ -induced chondrogenic differentiation of human BMSCs is more strongly inhibited by SMAD3 
knockdown than by SMAD2 knockdown is in line with the aforementioned study22. While we employed contin-
uous knockdown by viral transduction with shRNA, Furumatsu and co-workers employed transient knockdown 
by transfection with siRNA22. We, thus, verified that continuous knockdown of SMAD2 and SMAD3 had effects 
on chondrogenesis similar to transient knockdown.
Whereas the previous study has shown that SMAD3 overexpression accelerated chondrogenesis22, in our 
study SMAD3 overexpression blocked chondrogenic differentiation of human BMSCs. This discrepancy might be 
caused by a difference in chondrogenic media composition (details of medium components were not reported), 
cell source (fetal or adult origin, bone marrow or other tissue derived) or amount of overexpression (western 
blots of overexpressed SMAD3 were not shown). In addition, we found that the DNA content per pellet decreased 
over time in cells overexpressing SMAD3 (Supplementary Fig. S3). In multiple cell types, it has been shown that 
overexpression of SMAD3 leads to an inhibition of proliferation41–43. Importantly, proliferation of BMSCs early 
during chondrogenic differentiation is required for chondrogenesis44. Therefore, SMAD3 overexpression might 
have inhibited chondrogenesis, because it blocked proliferation. Overall, this indicates that constantly high levels 
of SMAD3 in BMSCs do not accelerate cartilage matrix formation. Since both knockdown and overexpression of 
SMAD3 inhibited chondrogenic differentiation, chondrogenesis seems to rely on well-balanced levels of SMAD3.
The present study, for the first time, investigated the role of SMAD4 during chondrogenic differentiation of 
human BMSCs. Previous studies in mice have demonstrated that mesenchyme-specific deletion of Smad4 leads 
to an absence of the limb skeleton as a result of impaired mesenchymal condensation30,31; a process required for 
initiating chondrogenesis45. In our study, SMAD4 knockdown did not interfere with pellet formation, implying 
that human BMSCs can form pellets even with a low amount of SMAD4. Although BMSCs transduced with 
SMAD4-shRNA formed pellets, they did not undergo chondrogenic differentiation. This observation is in line 
with a previous study demonstrating that BMSCs isolated from Smad4 knockout mice show reduced expression 
of Sox930. Additionally, we found that SMAD4 knockdown inhibited TGFβ -induced SMAD1/5/9 phosphoryl-
ation and expression of COL2A1; a direct transcriptional target of SOX946. In murine chondroprogenitor cells, 
complex formation between Smad4 and phosphorylated Smad1/5 proteins is required for transactivation of the 
Col2a1 promoter47. This might explain why chondrogenesis did not occur when we knocked down SMAD4. 
Furthermore, we previously demonstrated that the SMAD2/3 as well as the SMAD1/5/9 pathways are required 
for TGFβ -induced chondrogenesis of human BMSCs6,10. In the present study activation of both pathways was 
reduced by SMAD4 knockdown, thereby possibly explaining the absence of cartilage formation. Altogether, these 
findings underline the importance of SMAD4 during TGFβ -induced chondrogenic differentiation of human 
BMSCs.
Following chondrogenesis, BMSC-derived chondrocytes display signs of hypertrophic differentiation. This 
is undesired for the formation of articular cartilage, as hypertrophic chondrocytes produce cartilage that will 
mineralize and ossify when implanted in vivo7. We found that modulating SMAD2 expression did not have an 
effect on expression of hypertrophic differentiation markers, neither did SMAD4 overexpression. SMAD3 overex-
pression and SMAD4 knockdown did result in lower COL10A1 expression. In these conditions, however, next to 
hypertrophy markers, the markers of chondrogenesis were also much lower expressed than in the control condi-
tion, following the principle that reduced chondrogenesis leads to reduced hypertrophic differentiation. Whereas 
COL10A1 expression was lower by SMAD3 overexpression, RUNX2 expression was slightly, but significantly, 
higher. This was surprising, because SMAD3 is required for repression of RUNX2 expression and chondrocyte 
hypertrophy38,48–51. Possibly, as a result of decreased chondrogenesis RUNX2 expression failed to go down during 
the early phase of chondrogenesis or RUNX2 expression levels might depend on the abundance of SMAD3, but 
this requires further investigation. Overall, our results failed to show effects specifically on hypertrophic differen-
tiation of BMSC-derived chondrocytes without effects on the induction of chondrogenesis.
Besides the effects on chondrogenic and hypertrophic differentiation, this study investigated the effect of 
modulating SMAD2, SMAD3 and SMAD4 expression on TGFβ signal transduction. After activation by TGFβ, 
the ALK5 receptor phosphorylates SMAD2/3 proteins9. We show that SMAD2 phosphorylation was reduced 
by knockdown of SMAD2, while it highly increased by SMAD2 overexpression. These findings suggests that 
TGFβ -activated phosphorylation depends on the number of R-SMADs present in the cytoplasm rather than, for 
instance, on the kinase activity or number of ALK5 receptors.
We previously showed that TGFβ does not only induce phosphorylation of SMAD2/3, but also of SMAD1/5/9 
in BMSCs6,10,52. Although SMAD1/5/9 cannot be directly phosphorylated by the TGFβ receptor ALK5, 
TGFβ -activated SMAD1/5/9 phosphorylation requires the intracellular kinase domains of ALK540. Moreover, 
ALK5 is the only receptor through which TGFβ can induce phosphorylation of SMAD2/353,54. Consistent 
with a study showing enhanced pSMAD1/5/9 in SMAD3 knockout chondrocytes51, we demonstrate increased 
pSMAD1/5/9 when SMAD3 or SMAD2 were knocked down. This supports the idea that TGFβ -induced phos-
phorylation of SMAD1/5/9 requires the ALK5 receptor and is independent of other receptors that can activate 
SMAD1/5/955,56.
Although SMAD4 is an important co-factor for translocation of activated R-SMADs to the nucleus57, it has not 
been implicated in controlling the phosphorylation of R-SMADs. Patients with Myhre syndrome have mutations 
in SMAD4 that lead to decreased ubiquitination of SMAD4 protein, resulting in accumulation of SMAD458–61. 
In skin fibroblasts from these patients, pSMAD2/3 and pSMAD1/5/9 were enhanced compared to healthy con-
trols58,61. Contrary to this, in our study SMAD4 overexpression had no effect on R-SMAD phosphorylation. On 
the other hand, SMAD4 knockdown reduced TGFβ -induced phosphorylation of SMAD2 and completely pre-
vented SMAD1/5/9 phosphorylation. Based on these observations, we speculate that SMAD4 is required for 
R-SMAD phosphorylation, or prevents R-SMADs from de-phosphorylation62,63 or ubiquitination64,65, which adds 
a regulatory mechanism that controls TGFβ signal transduction.
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To conclude, this study reveals that TGFβ -activated phosphorylation of R-SMADs in BMSCs does not only 
depend on the levels of SMAD2 and SMAD3, but also on the presence of SMAD4. Moreover, our findings suggest 
that SMAD3 and SMAD4 are more important than SMAD2 for TGFβ -induced chondrogenic differentiation of 
human BMSCs. However, as cartilage formation was not enhanced by overexpression of SMAD4 and even inhib-
ited by SMAD3 overexpression, induction of chondrogenic differentiation seems to rely on a delicate balance 
in the amount of SMAD3 and SMAD4. This also implies that continuously enhanced SMAD3 expression levels 
may not be a suitable strategy to improve chondrogenesis. Despite its exploratory nature, this study offers novel 
insights into the signaling mechanism governing the induction of chondrogenic differentiation of human BMSCs. 
Further research is required to delineate the function of SMAD4 in TGFβ -induced phosphorylation of R-SMADs 
and the mechanisms behind the detrimental effects of SMAD3 overexpression on chondrogenesis.
Methods
Culturing of human fetal bone marrow-derived mesenchymal stem cells. Human fetal BMSCs 
(#SCC7500, Lot#6890, ScienCell Research Laboratories, Carlsbad, CA, USA) were expanded in Mesenchymal 
Stem Cell Growth Medium (MSCGM™ ; Lonza, Basel, Switzerland) supplemented with 1% Penicillin-
Streptomycin-Glutamine (Gibco, Carlsbad, CA, USA). Cells were cultured in a 37 °C-incubator with 5% CO2. 
After reaching 80% confluence, cells were passaged using 0.05% trypsin-EDTA (Gibco) and re-seeded (~6,000 
cells/cm2) in MSCGM. After 4 passages, cells were stored in liquid nitrogen. Per experiment, fetal BMSCs were 
defrosted and expanded in MSCGM for another 2 or 3 passages.
Induction of chondrogenic differentiation. BMSC pellets were obtained by centrifuging 200,000 cells 
at 300 × g for 8 minutes in polystyrene V-bottom tubes (Greiner Bio-One, Alphen a/d Rijn, Netherlands). Pellets 
were cultured for 1, 7 or 14 days in 0.5 mL of serum-free chondrogenic medium, which consisted of DMEM-high 
glucose-GlutaMAX, 1% Penicillin-Streptomycin-Glutamine (both from Gibco), 6.25 μ g/mL Insulin, 6.25 μ g/mL 
Transferrin, 6.25 ng/mL selenious acid 5.35 μ g/mL linoleic acid, 1.25 mg/mL bovine serum albumin, 1.0 mg/mL 
sodium pyruvate, 0.4 mg/mL L-proline, 50 μ g/mL sodium L-ascorbate, 10−7 M dexamethasone (all from 
Sigma-Aldrich), and 10 ng/mL TGFβ 1 (Biolegend, San Diego, CA, USA). This medium was renewed 3 times per 
week.
Short hairpin-mediated knockdown of SMAD2, SMAD3 or SMAD4. MISSION® TRC-Hs1.5 shRNA 
clones targeting SMAD2 (TRCN0000040036), SMAD3 (TRCN0000330056) or SMAD4 (TRCN0000010321), and 
Non-Mammalian shRNA control (SHC002) constructed in the pLKO.1-Puro plasmid vector were obtained from 
Sigma-Aldrich. Lentiviruses were packaged as described previously10. Briefly, HEK293T cells (ATCC, Manassas, 
VA, USA) were co-transduced with plasmids of Rev, Gag, Pol, VSV-G (Plasmid Factory, Bielefeld, Germany) and a 
pLKO.1-Puro plasmid vector by calcium phosphate precipitation in DMEM (Gibco) containing 10% FCS (Perbio 
Science, Erembodegem, Belgium), 0.01 mM cholesterol (Sigma-Aldrich) and 1% pyruvate (Gibco). Medium was 
renewed at day 1, 2 and 3 post-transduction, collecting the medium at day 2 and 3. Collected medium was filtered 
through a 0.45 μ m filter and centrifuged at 134,350 × g for 2 hours (Sorvall WX80+ , ThermoFisher Scientific). 
Lentivirus concentration was determined with the INNOTEST® HIV p24 Antigen assay (Fujirebio Europe, Gent, 
Belgium) and expressed as pg of p24/μ L.
At 20% confluence, BMSCs were infected with 1 pg p24 per cell in MSCGM (Lonza) supplemented with 100 μ 
g/mL protamine sulfate (Sigma-Aldrich) for 1 day. After culture-expanding infected cells for 2 days, pellets were 
prepared to induce chondrogenesis. 1 day after pellet preparation, the efficiency of shRNA-mediated knockdown 
of SMAD2, SMAD3 and SMAD4 was analyzed by RT-qPCR and Western blot.
Adenoviral-mediated overexpression of SMAD2, SMAD3 or SMAD4. Adenoviruses for 
SMAD2, SMAD3 and SMAD4 were kindly provided by Dr. P. ten Dijke (Leiden University Medical Center, the 
Netherlands). Cells at 80% confluence were incubated for 3 hours with adenovirus (multiplicity of infection of 1 
pfu/cell) overexpressing either SMAD2, SMAD3, SMAD4 or LacZ (control). Following transduction, cells were 
washed and centrifuged to obtain pellets for chondrogenic induction. Overexpression of SMAD2, SMAD3 and 
SMAD4 was verified at gene (RT-qPCR) and protein (Western blot) level in BMSCs cultured for 1 day in chon-
drogenic medium.
Western blot analysis of (phosphorylated) SMAD proteins. To evaluate the effects of SMAD knock-
down and overexpression on activation of TGFβ signaling, cells transduced either with lentivirus (SMAD-shRNA) 
or adenovirus (SMAD overexpression) were seeded in chondrogenic medium without TGFβ . After 18 hours, cells 
were stimulated with 10 ng/mL TGFβ 1 (Biolegend) for 1 hour and cell lysates were prepared as described below to 
determine pSMAD2 and pSMAD1/5/9 expression.
To determine protein abundance, cells were lysed (duplicate per condition) using lysis buffer 
(Cell-Signaling-Technology, Danvers, MA, USA) containing 1% protease inhibitor (Roche, Mannheim, 
Germany) and lysates were sonicated on ice. Protein concentration was determined using bicinchoninic acid 
assay. Duplicate samples per condition were pooled and 10 μ g protein lysate was subjected to 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose membranes and overnight 
at 4 °C incubated with an antibody (1:1,000) recognizing SMAD2 (#40855, Abcam, Cambridge, UK), SMAD3 
(#28379, Abcam), SMAD4 (#AF2097, R&D systems, Minneapolis, MN, USA), pSMAD2 (#3101 L, Cell Signaling 
Technology) or pSMAD1/5/9 (#9511 L, Cell Signaling Technology). Subsequently, membranes were incubated 
with HRP-linked antibody (1:1,500) against rabbit-IgG (#P0448, Dako, Glostrup, Denmark) or against goat-IgG 
(#P0449, Dako) for 1 hour at room temperature. To evaluate equal protein loading between conditions, GAPDH 
expression was determined. Membranes were overnight incubated with an antibody (1:20,000) recognizing 
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GAPDH (#G8795, Sigma-Aldrich), followed by 1 hour-incubation with HRP-linked antibody (1:1,500) against 
mouse-IgG (#P0260, Dako). Proteins were visualized by enhanced chemiluminescence using Prime Western 
Blotting Detection Reagent and a ImageQuant LAS4000 machine (GE Healthcare). Densitometry was performed 
using ImageJ software (release 1.46r; National Institute of Health, Bethesda, Maryland, USA).
RNA extraction and gene expression analysis. Pellets (n = 3 per condition at each time point) were 
collected in TRIzol® (Sigma-Aldrich) and disrupted using MagNA Lyser instrument (Roche). After total RNA 
was isolated according to manufacturer’s protocol (Sigma-Aldrich), RNA samples were treated with DNAse 
(Invitrogen) to remove contaminating genomic DNA. RNA concentration and purity were measured using a 
NanoDrop® spectrophotometer (Isogen Life Science, Utrecht, the Netherlands). 0.5 μ g RNA was reverse tran-
scribed in cDNA with M-MLV Reverse Transcriptase (Invitrogen). Gene expression was measured by real-time 
Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) on a StepOnePlus™ System using 
SYBR Green Master mix (Applied Biosystems) and the primers listed in Table 1. CT values were determined at a 
fixed threshold level of fluorescence and efficiency of all primers was between 90% and 110% (Table 1). Data were 
normalized to the mean CT value of Ribosomal protein 27a (RPS27A) and TATA-box binding protein (TBP). The 
following genes were used as markers of chondrogenesis; Aggrecan (ACAN), Collagen type IIα1 (COL2A1) and 
SRY (Sex Determining Region Y)-Box 9 (SOX9). In addition, markers of chondrocyte hypertrophy; collagen type 
10 α1 (COL10A1) and runt-related transcription factor 2 (RUNX2), were measured.
Histology. To macroscopically evaluate pellet size of 14-days cultured pellets, pictures were taken using 
a microscope (Wild M3B, Heerbrugg, Switzerland). Subsequently, pellets were fixed in 4% formalin for 
14 hours, embedded in paraffin and sectioned (6 μ m). Sections were stained with 0.1% aqueous Safranin O 
(Brunschwig Chemie, Amsterdam, the Netherlands), resulting in red-staining of negatively-charged GAGs. As 
counter-staining, 0.1% aqueous Fast Green (Brunschwig Chemie) was used to stain the cytoplasm blue/green.
For immunohistochemical staining of collagen type II, sections were pre-treated with 1 mg/mL pronase and 
10 mg/mL hyaluronidase (Sigma-Aldrich), and then incubated with 0.4 μ g/mL antibody specific for collagen type 
II (#II-II6B3, Developmental Studies Hybridoma Bank, Iowa City, IA, USA) or 0.4 μ g/mL mouse-IgG1 (#X0931, 
Dako, Glostrup, Denmark). Following incubation with alkaline phosphatase (AP)-conjugated secondary anti-
body (1:50, #HK-321-UK, Biogenex, San Ramon, CA, USA), AP-activity was visualized (magenta color) by incu-
bation with new-fuchsin substrate. Sections were counterstained with haematoxylin (purple) to visualize nuclei.
Glycosaminoglycans and DNA content measurements. Pellets cultured for 1, 7 or 14 days were 
digested overnight at 60 °C in 100 μ L papain digestion buffer (pH = 6.4) containing 0.1% papain, 10 mM 
EDTA-disodium salt (both from Merck), 100 mM sodium acetate, and 5 mM L-Cysteine·HCL (both from 
Sigma-Aldrich). Following digestion, samples were diluted 1:8 in water to measure the GAG content or samples 
were diluted 1:6 in Tris-EDTA (TE) buffer to measure DNA content. The GAG content was measured by adding 
200 μ L dimethylmethylene blue (DMB) solution (0.05 mM DMB, 41 mM NaCl, 45 mM glycin and pH = 3.0) to 
40 μ L papain-digested sample (pre-diluted 1:8 in water) and absorbance was measured at 590 nm using an iMark 
Reader (Bio-Rad). To determine the DNA content, PicoGreen® stock solution (ThermoFisher Scientific) was 
diluted 1:200 in TE buffer (10 mM Tris-HCl, 1 mM EDTA and pH = 7.5) and 50 μ L of this solution was mixed 
with 50 μ L papain-digested sample (pre-diluted 1:6 in TE buffer). After 5 minutes dark incubation at room tem-
perature, fluorescence was measured at 485/520 nm (excitation/emission) with a CLARIOstar (BMG Labtech, 
Offenburg, Germany) using DNA obtained from human HEK293T cells to set the standard curve.
Data analysis. Data represent mean + standard deviation of 6 pellets (from two experiments with triplicate 
pellets per experiment) per condition per time point. Statistical analyses were performed using SPSS version 22 
(IBM, Armonk, NY, USA). Normality and variance were verified with the Shapiro-Wilk test and Levene’s Test, 
respectively. Statistical differences between control and experimental conditions per time point were determined 
with two-tailed independent T-tests. Level of significance was set at P < 0.05.
Gene Forward primer Reverse primer Product
RPS27A TGGCTGTCCTGAAATATTATAAGGT CCCCAGCACCACATTCATCA 90 bp
TBP GCTTCGGAGAGTTCTGGGATTG GCAGCAAACCGCTTGGGATTA 134 bp
SMAD2 CCGACACACCGAGATCCTAAC AGGAGGTGGCGTTTCTGGAAT 127 bp
SMAD3 CATCGAGCCCCAGAGCAATA GTGGTTCATCTGGTGGTCACT 88 bp
SMAD4 CCAATCATCCTGCTCCTGAGT CCAGAAGGGTCCACGTATCC 130 bp
ACAN GCCTGCGCTCCAATGACT ATGGAACACGATGCCTTTCAC 104 bp
COL2A1 CACGTACACTGCCCTGAAGGA CGATAACAGTCTTGCCCCACTT 65 bp
SOX9 TGGGCAAGCTCTGGAGACTT CCCGTTCTTCACCGACTTCCT 140 bp
COL10A1 TTTTACGCTGAACGATACCAAATG CTGTGTCTTGGTGTTGGGTAGTG 66 bp
RUNX2 GCAAGGTTCAACGATCTGAGA TTCCCGAGGTCCATCTACTG 141 bp
Table 1.  List of primers used for RT-qPCR.
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